Tumor necrosis factor as mediator of inflammatory diseases and its therapeutic targeting: A review

Journal of Medical Sciences (Faisalabad)

Volumn 13, Issue 4, 2013, Pages 226-235

  Dhama, Kuldeep ^a   Latheef, Shyma K ^b   Samad, Hari Abdul ^a   Chakraborty, Sandip ^c   Tiwari, Ruchi ^d   Kumar, Amit ^d   Rahal, Anu ^e  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^b Ch Charan Singh Haryana Agric U   (India)

^c Animal Resources Development Department Pandit Nehru Complex   (India)

^d Department of Veterinary Microbiology and Immunology ^*  (India)

^e Uttar Pradesh Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go Anusandhan Sansthan   (India)

Author keywords

Autoimmunity; Cytokine; Disease; Inflammation; Ligand; Malignancy; Therapy; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CD134 ANTIGEN; CD137 ANTIGEN; CD30 ANTIGEN; CD70 ANTIGEN; CERTOLIZUMAB PEGOL; CISPLATIN; DEATH RECEPTOR 3; ETANERCEPT; INFLIXIMAB; LENERCEPT; LYMPHOTOXIN; OX40 LIGAND; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC ENCEPHALOMYELITIS; ANKYLOSING SPONDYLITIS; ASTHMA; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE SYNDROME; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEPHROTOXICITY; NONHUMAN; PSORIASIS; PSORIATIC ARTHRITIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84877974125     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2013.226.235     Document Type: Review

References (78)

1. Al-Lamki, R.S., J. Wang, P. Vandenabeele, J.A. Bradley and S. Thiru, 2005. TNFRr and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEBJ., 19: 1637-1645.
2. Al-Lamki, R.S., T.J. Sadler, J. Wang, M.J. Reid and A.Y. Warren et al., 2010. Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am. J. Pathol., 177: 943-954.
3. Arnett, H.A., J. Mason, M. Marino, K. Suzuki, G.K. Matsushima and J.P. Ting, 2001. TNFa promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci., 4: 1116-1122.
4. Ashkenazi, A. and V.M. Dixit, 1998. Death receptors: Signaling and modulation. Science, 281: 1305-1308.
5. Bach, E.A., M. Aguet and RD. Schreiber, 1997. The TFN-y receptor: A paradigm for cytokine receptor signaling. Annu. Rev. Immunol., 15: 563-591.
6. Balkwill, F., 2006. TNF-[3 in promotion and progression of cancer. Cancer Metastasis Rev., 25: 409-416.
7. Behrendt, A.K. and G. Hansen, 2010. CD27 costimulation is not critical for the development of asthma and respiratory tolerance in a murine model. Immunol. Lett, 133: 19-27.
8. Bradley, J.R., 2008. TNF-mediated inflammatory disease. J. Pathol., 214: 149-160.
9. Castro, J.E., J.A. Listman, B.A. Jacobson, Y. Wang and P.A. Lopez et al., 1996. Fas modulation of apoptosis during negative selection of thymocytes. Immunity, 5: 617-627.
10. Chang, J.H., Y.S. Ryang, T. Mono, S.K. Lee and E.J. Chang, 2004. Trichomonas vaginalis inhibits proinflammatory cytokine production in macrophages by suppressing NF-kappaB activation. Mol. Cells, 18: 177-185.
11. Chaudhari, U., P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker and A.B. Gottlieb, 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet, 357: 1842-1847.
12. Chauhan, R.S. and K. Dhama, 2008. Cowpathy in induction of cytokines and its importance in control of human and animal diseases. Ibied, Souvenir, pp: 117-121
13. Clark, J., P. Vagenas, M. Panesar and A.P. Cope, 2005. Structural and functional footprints of the tnf/tnf-r superfamily. Ann. Rheum. Dis., 64: iv70-iv76.
14. Croft, M., 2003a. Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity? Nat. Rev. Immunol, 3: 609-620.
15. Croft, M., 2003b. Costimulation of T cells by OX40, 4-1BB andCD27. Cytokine Growth Factor Rev., 14: 265-273.
16. Croft, M., 2009. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol., 9: 271-285.
17. Croft, M., 2010. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol., 28: 57-78.
18. Croft M., W. Duan, H. Choi, S. Eun, S. Madireddi and A. Mehta, 2012. TNF superfamily in inflammatory disease: Translating basic insights. Trends Immunol., 33: 144-153.
19. Darnell Jr., J.E., 1997. STATs and gene regulation. Science, 332: 1630-1633.
20. Deb, R., S. Chakraborty, B.M. Veeregowda, A.K. Verma, R. Tiwari and K. Dhama, 2013. Monoclonal antibody and its use in the diagnosis of livestock diseases. Adv. Biosci. Biotechnol.
21. Dhama, K., R.S. Chauhan and L.K. Singhal, 2005. Anti-cancer activity of cow urine: Current status and future directions. Int. J. Cow Sci., 1: 1-25.
22. Dhama, K., R. Rathore, RS. Chauhan and T. Simmi, 2005. Panchgavya: An overview. Int. J. Cow Sci., 1: 1-15.
23. Dhama, K. and R.S. Chauhan, 2008. Cytokines and the inflammatory responses: An overview. Proceedings of the Compendium of Training cum Workshop on Cytokine, February 26-27, 2008, Mathura, UP., India, pp: 17-33.
24. Dhama, K., M. Mahendran, R.S. Chauhan and S. Tomar, 2008. Cytokines-Their functional roles and prospective applications in Veterinary practice: A review. J. Immunol. Immunopathol., 10: 79-89.
25. Dhama, K., A. Hansa and F. Anjaneya, 2011. Cytokine therapy for animal diseases: The perspectives. Livestock Line, Vol. 4.
26. Dhama, K., S. Chakraborty, Mahima, M.Y. Wani and A.K. Verma et al, 2013. Novel and emerging therapies safeguarding health of humans and their companion animals: A review. Pak. J. Biol. Sci., 16: 101-111.
27. Dolff, S., D. Quandt, B. Wilde, T. Feldkamp and F. Hua et al, 2010. Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. Arthritis Res. Ther., Vol. 12. 10.1186/ar3100
28. Esposito, E. and S. Cuzzocrea, 2009. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr. Med. Chem., 16: 3152-3167.
29. Fang, L., B. Adkins, V. Deyev and E.R. Podack, 2008. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J. Exp. Med., 205: 1037-1048.
30. Fousteri, G., A. Dave, B. Morin, S. Omid, M. Croft and M.G. Von Herrath, 2011. Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J. Autoimmun., 36: 210-220.
31. Francois, R.J., L. Neure, J. Sieper and J. Braun, 2006. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann. Rheumat. Dis., 65: 713-720.
32. Gabay, C. and I. Kushner, 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med., 340: 448-454.
33. Galuppo, M., G. Nocentini, E. Mazzon, S. Ronchetti and E. Esposito et al, 2011. The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice. Br. J. Pharmacol., 162: 1186-1201.
34. Geiler, J., M. Buch and M.F. McDermott, 2011. Anti-TNF treatment in rheumatoid arthritis. Curr. Pharm. Des., 17: 3141-3154.
35. Gillett, A., M. Marta, T. Jin, J. Tuncel and P. Leclerc et al, 2010. TNF production in macrophages is genetically determined and regulates inflammatory disease in rats. J. Immunol, 185: 442-450.
36. Gottlieb, A.B., R. Evans, S. Li, L.M.T. Dooley and C.A. Guzzo et al, 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo controlled trial. J. Am. Acad. Dermatol., 51: 534-542.
37. Haritunians, T., K.D. Taylor, S.R. Targan, M.D.M. Dubinsky and M.D.A. Ippoliti et al, 2010. Genetic predictors of medically refractory ulcerative colitis. Inflamm. Bowel Dis., 16: 1830-1840.
38. Hotamisligil, G.S., N.S. Shargill and B.M. Spiegelman, 1993. Adipose expression of tumor necrosis factor-a: Direct role in obesity-linked insulin resistance. Science, 259: 87-91.
39. Jung, J.H., Y.S. Chae, J.H. Moon, B.W. Kang and J.G. Kim et al, 2010. TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J. Cancer Res. Clin. Oncol, 136: 685-694.
40. Khare, S.D., I. Sarosi, X. Xia, S. McCabe and K. Miner et al, 2000. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci., 97: 3370-3375.
41. Kodama, S., M. Davis and D.L. Faustmana, 2005. The therapeutic potential of tumor necrosis factor for autoimmune disease: A mechanistically based hypothesis. Cell. Mol. Life Sci., 62: 1850-1862.
42. Lange, U., J. Teichmann and H. Stracke, 2000. Correlation between plasma TNFá, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity and clinical manifestations in ankylosing spondylitis. Eur. J. Med. Res., 5: 507-511.
43. Lee, B.H., S.Y. Park, K.B. Kang, R.W. Park and IS. Kim, 2002. NF-kappaB activates fibronectin gene expression in rat hepatocytes. Biochem. Biophys. Res. Commun, 297: 1218-1224.
44. Leung, L. and CM. Cahill, 2010. TNF-[3 and neuropathic pain: A review. J. Neuroinflammation, Vol. 7. 10.1186/1742-2094-7-27
45. Lievens, D., A. Zernecke, T. Seijkens, O. Soehnlein and L. Beckers et al, 2010. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood, 116: 4317-4327.
46. Locksley, R.M., N. Killeen and M.J. Lenardo, 2001. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell, 104: 487-501.
47. Mahima, A. Rahal, R. Deb, S.K. Latheef and H.A. Samad et al, 2012. Immunomodulatory and therapeutic potentials of herbal, traditional/indigenous and ethnoveterinary medicines. Pak. J. Biol. Sci., 15: 754-774.
48. Mark, K.S., W.J. Trickier and D.W. Miller, 2001. Tumor necrosis factor-á induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J. Pharmacol. Exp. Ther.,297: 1051-1058.
49. Meylan, F., YJ. Song, I. Fuss, S. Villarreal and E. Kahle et al, 2011. The TNF-family cytokme TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol., 4: 172-185.
50. Mukhopadhyay, S., J.R. Hoidal and T.K. Mukherjee, 2006. Role of TNFá in pulmonary pathophysiology. Respir. Res., Vol. 7. 10.1186/1465-9921-7-125
51. Nawashiro, H., D. Martin and J.M. Hallenbeck, 1997. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res., 778: 265-271.
52. Nguyen, Q.T., S.A. Ju, S.M. Park, S.C. Lee, H. Yagita, I.H. Lee and B.S. Kim, 2009. Blockade of CD137 signaling counteracts polymicrobial sepsis induced by cecal ligation and puncture. Infect. Immunity, 77: 3932-3938.
53. Nolte, M.A., R.W. van Olffen, K.P.J.M. van Gisbergen and R.A.W. vanLier, 2009. Timing and tuning of CD27-CD70 interactions: The impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev., 229: 216-231.
54. Oflazoglu, E., IS. Grewal and H. Gerber, 2009. Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases. In: Therapeutic Targets of the TNF Superfamily, Grewal, IS. (Ed.). Springer, New York, USA, ISBN-13: 9780387895192, pp: 174-185.
55. Peters, A.L., L.L. Stunz and G.A. Bishop, 2009. CD40 and autoimmunity: The dark side of a great activator. Semin. Immunol, 21: 293-300.
56. Pfeffer, K., T. Matsuyama, T.M. Kundig, A. Wakeham and K. Kishihara et al, 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell, 73: 457-467.
57. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang and P. Koebel et al, 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature, 364: 798-802.
58. Sands, B.E., F.H. Anderson, C.N. Bernstein, W.Y. Chey and B.G. Feaganeia, 2004. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med., 350: 876-885.
59. Shu, H.B., W.H. Hu and H. Johnson, 1999. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leukocyte Biol., 65: 680-683.
60. Siddiqui, S., V. Mistry, C. Doe, S. Stinson, M. Foster and C. Brightling, 2010. Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest, 137: 797-804.
61. Sumi, T., W. Ishida, A. Ojima, M. Kajisako, T. Sakanishi, H. Yagita and A. Fukushima, 2008. CD27 and CD70 do not play a critical role in the development of experimental allergic conjunctivitis in mice. Immunol. Lett, 119: 91-96.
62. Sun, X., H. Yamada, K. Shibata, H. Muta 2010. CD30 ligand is a target for a novel biological therapy against colitis associated withThl7 responses. J. Immunol., 185: 7671-7680.
63. Sun, X., S. Somada, K. Shibata, H. Muta and H. Yamada et al, 2008. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology, 134: 447-458.
64. Szlosarek, P.W. and F.R. Balkwill, 2003. Tumour necrosis factor á: A potential target for the therapy of solid tumours. Lancet Oncol., 4: 565-573.
65. Tansey, M.G. and D.E. Szymkowski, 2009. The TNF superfamily in 2009: New pathways, new indications and new drugs. Drug Discovery Today, 14: 1082-1088.
66. Taylor, L., M. Bachler, I. Duncan, S. Keen and R. Fallon et al, 2002. In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isofoims with different levels of immune-effector functions. J. Leukocyte Biol, 72: 522-529.
67. Thompson, A.E., S.W. Rieder and J.E. Pope, 2011. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheumatism, 63: 1479-1485.
68. Tizard, I.R., 2004. Cytokines and the Immune System. In: Veterinary Immunology: An Introduction, Tizard, I.R. (Ed.). 7th Edn. Saunders, Pennsylvania, USA., pp: 133-144.
69. Tracey, D., L. Klareskog, E.H. Sasso, J.G. Salfeld and P.P. Tak, 2008. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther., 117: 244-279.
70. Tracey, K.J. and A. Cerami, 1994. Tumor necrosis factor: A pleiotropic cytokine and therapuetic target. Annu. Rev. Med., 45: 491-503.
71. Tremelling, M., C. Berzuini, D. Massey, F. Bredin 2008. Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population. Inflamm. Bowel Dis., 14: 733-737.
72. Tyring, S., K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, M. Dunn and A. Jahreis, 2007. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol., 143: 719-726.
73. Watkins, L.R., S.F. Maier and L.E. Goehler, 1995. Immune activation: The role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain, 63: 289-302.
74. Wolfe, F. and K. Michaud, 2004. Heart failure in rheumatoid arthritis: Rates, predictors and the effect of anti-tumor necrosis factor therapy. Am. J. Med., 116: 305-311.
75. Yang, J., Y. Chu, X. Yang, D. Gao and L. Zhu et al, 2009. Thl 7 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum., 60: 1472-1483.
76. Zhang, J., X. Wang, H. Fahmi, S. Wojcik 2009. Role of TL1A in the pathogenesis of rheumatoid arthritis. J. Immunol., 183: 5350-5357.
77. Zhang, Z., W. Zhong, D. Hinrichs, X. Wu and A. Weinberg 2010. Activation of OX40 augments Thl 7 cytokine expression and antigen-specific uveitis. Am. J. Pathol, 177: 2912-2920.
78. Zimmerer, J.M., P.H. Home, L.A. Fiessinger, M.G. Fisher, T.A. Pham, S.L. Saklayen and G.L. Bumgardner, 2012. Cytotoxic effector function of CD4-independent, CD8+ T cells is mediated by TNF-pVTNFR. Transplantation, 94: 1103-1110.